Podcast Episode
1: The story of Berry Consultants
Subscribe to In the Interim...
February 24, 2025
No items found.
Discover the transformative journey of Berry Consultants, pioneers in adaptive clinical trials, and their impact on the future of medical research.
In the inaugural episode of Berry's "In the Interim...," we sit down with the founders of Berry Consultants, Dr. Don Berry and Dr. Scott Berry. Celebrating their 25th anniversary as a company, they explore the pioneering journey of their firm, known for transforming the landscape of clinical trials with their adaptive and Bayesian methodologies. With stories from their early days to innovative projects on the horizon, this episode provides a fascinating look into how Berry Consultants is redefining clinical research and impacting global health.
Key Highlights
- The founding story of Berry Consultants and the inspiration behind their unique approach to clinical trials.
- Challenges faced in pioneering adaptive trials and overcoming regulatory hurdles.
- Key collaborations and the influence of FDA approvals in their adaptive trial designs.
- The revolutionary impact of platform trials developed by Berry Consultants during the COVID pandemic.
- Future innovations and aspirations for the next 25 years in clinical trial design.
Quotes
- "We really were providing the service that they didn’t know they needed." – Dr. Don Berry
- "Our methodology allows the client to be the biggest advocate for the direction they're going." – Dr. Scott Berry
- "We want to change the world, one person at a time." – Dr. Don Berry
Download PDF
View
9: I-SPY 2 to GBM AGILE and Beyond
In this episode of "In the Interim...," we sit down with Dr. Meredith Buxton to explore the evolution of platform trials from I-SPY 2 to GBM AGILE and Beyond.
8: External Data in Clinical Trials
In this episode of "In the Interim...," Scott Berry and Kert Viele navigate the nuanced debate surrounding the integration of external data in clinical trials.
7: Remembering Jimmie Savage
In this episode of "In the Interim," Don Berry shares the life and work of Jimmie Savage, his advisor and a legendary figure in Bayesian statistics.
6: The Art and Slog of Innovating
In this compelling episode of "In the Interim," Dr. Mike Krams, a seasoned expert in clinical trials and drug development, joins us to discuss the art and slog of innovation in pharmaceutical companies.
5: Religion, Politics, and Ordinal Outcomes
In this episode of "In the Interim," Scott Berry discusses the vital topic of ordinal outcomes in clinical trials—a subject as controversial as politics and religion at the dinner table.
4: HEALEY ALS Platform Trial with Dr. Merit Cudkowicz and Dr. Melanie Quintana
In this episode of the podcast, we sit down with Dr. Merit Cudkowicz and Dr. Melanie Quintana to discuss the inception and execution of the Healy ALS Platform Trial, a revolutionary approach designed for efficiency and impactful data collection.
3: FACTS 7.1 Release with Tom Parke
In this episode of In the Interim, Berry's Director of Software, Tom Parke, discusses the intricacies and updates surrounding FACTS, a sophisticated clinical trial simulation software.
2: When should you use adaptive design clinical trials?
In this episode of "In the Interim," we consider the nuances of adaptive design clinical trials with distinguished guests Dr. Scott Berry and Dr. Kert Viele from Berry Consultants. The conversation centers around the vital question: when should these adaptive designs be implemented?
1: The story of Berry Consultants
Discover the transformative journey of Berry Consultants, pioneers in adaptive clinical trials, and their impact on the future of medical research.